Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

Ala Ghobadian, Saba Mokhtari, Behnam Shariati, Leila Kamalzadeh, Mohsen Shati, Mehrdad Eftekhar Ardebili, Masoomeh Yarahmadi and Mohammadreza Shalbafan

Abstract

Background  Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20–30%, and satisfactory treatment is obtained in 40–60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the patients’ function. Therefore, it is necessary to investigate possible strategies to improve the mitigation of symptoms. In this study, the main objective was to examine and investigate the effectiveness of granisetron, which is a serotonin 5-hydroxytryptamine receptor type 3 (5-HT₃) antagonist, as an adjunct therapy to selective serotonin reuptake inhibitors, for the purpose of ameliorating OCD symptoms.

Methods  Fifty-eight patients diagnosed with OCD, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, who had a Yale-Brown obsessive-compulsive scale (Y-BOCS) score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either granisetron (1 mg twice daily) and sertraline (100 mg daily initially followed by 200 mg daily after week 4) or placebo and sertraline. The primary outcome was OCD symptoms measured by the Y-BOCS.

Results  Y-BOCS total score significantly dropped in both groups (28.9 to 17.7 for granisetron plus sertraline and 27.5 to 19.3 for placebo plus sertraline group with a slightly greater drop for granisetron plus sertraline group), while the granisetron plus sertraline group experienced a significantly greater reduction in obsession scores (Greenhouse-Geisser F(2.32,97.57) = 4.52, p-value = 0.01). Moreover, in comparison with the placebo plus sertraline group, the proportion of the patients showing complete response was considerably higher among the granisetron plus sertraline group (P-value < 0.01). No major adverse effects were observed in any of the groups.
In fact, recent research has shown the important role of antagonists for OCD are not yet totally conclusive [studies are not conclusive on the actual benefit of 5-HT-nists for the treatment of patients with OCD. Overall, the potential efficacy and safety of 5-HT and only two studies have attempted to investigate the successfully used to treat OCD [1].

OCD-related symptoms [2]. It is used to effectively prevent post-chemotherapy, post-radiotherapy, or post-surgery nausea and vomiting. Due to its high lipophilicity, granisetron is an ideal choice to pass the blood-brain barrier and to be used in nervous system disorders [3].

Currently, selective serotonin reuptake inhibitors (SSRIs) and/or cognitive behavioral therapy (CBT), particularly exposure and response prevention (ERP), are considered first-line treatments for OCD [4]. SSRIs usually reduce the effect and severity of OCD symptoms by as much as 20–30% [5]. Satisfactory treatment is obtained in 40–60% of patients with OCD [6]. Nevertheless, the remaining symptoms continue to impair the patients’ function. For patients who do not respond adequately to first-line treatments, combination therapy of CBT and SSRIs, pharmacological augmentation of SSRIs, and changing SSRIs to another drug (in case there is a specific SSRI resistance) are used as second-line therapies [7].

Granisetron is a highly selective and potent 5-HT3 receptor antagonist which has very little or no affinity for other receptors [8]. It is used to effectively prevent post-chemotherapy, post-radiotherapy, or post-surgery nausea and vomiting. Due to its high lipophilicity, granisetron is an ideal choice to pass the blood-brain barrier and to be used in nervous system disorders.

Even if, some previous studies have shown positive effects of the 5-HT3 receptor antagonists (e.g., ondansetron and granisetron) in augmentation with SSRIs on OCD-related symptoms [9] and recent evidence suggests that ondansetron and tropisetron (other members of the 5-HT3 receptor antagonist family) have been successfully used to treat OCD [10, 11–13]. However, no animal OCD models have directly implicated 5-HT3 receptors and only two studies have attempted to investigate the efficacy of granisetron for the treatment of OCD [14, 15].

Despite this, the results of these studies supported the potential efficacy and safety of 5-HT3 receptor antagonists for the treatment of patients with OCD. Overall, the studies are not conclusive on the actual benefit of 5-HT3 antagonists for OCD are not yet totally conclusive [16].

The use of antiemetics in OCD is not unreasonable. In fact, recent research has shown the important role of disgust in the symptoms of OCD. Excessive disgust reactions may cause some of the symptoms of OCD, and in many cases, can even overshadow the anxiety symptoms [17]. One of the models of the pathology of nausea is based on conditioned and learned disgust [18] and some studies showed the superiority of this hypothesis on rats [19]. Moreover, nausea is one of the important adverse effects of serotonin reuptake inhibitors (SSRIs) and it can reduce compliance to medication. Using 5-HT3 blockers, as augmentation therapy maybe the preferred choice especially in cases of drug-induced nausea [20].

Granisetron has a better tolerability profile, a lower drug-drug interaction, no effect on the activity of cytochrome P450, and a longer duration of action amongst other 5-HT3 receptor antagonists [21]. Also, it is well-known that sertraline has the lowest drug interaction among SSRIs approved for the treatment of OCD [22]. These benefits make these two drugs suitable choices as augmentation to evaluate their therapeutic effects on patients with OCD.

Given the need to find new options to increase OCD patients’ treatment responsiveness, this study aimed to investigate the additional benefits of granisetron augmentation therapy with sertraline in OCD symptom reduction compared to sertraline alone.

**Methods**

**Trial setting and design**

A 10-week, double-blind, randomized, placebo-controlled, parallel-group trial was performed at the outpatient clinics of Iran Psychiatric Hospital and Tehran Psychiatric Institute (affiliated with Iran University of Medical Sciences, Tehran, Iran) from April to December 2019.

**Participants**

Patients, aged 18–60 years, with a clinical diagnosis of OCD based on DSM-5 criteria, were screened for the study [23]. Those with a diagnosis of moderate-to-severe OCD, defined by a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥21 were included [24, 25].

The patients attending the clinics were consecutively checked for the entry criteria and recruited until the sample size was achieved. All of the patients enrolled in the study were assessed with a structured clinical interview designed in accordance with the DSM-5 by an expert psychiatrist [26].
The exclusion criteria were: (1) the presence of life-threatening psychiatric symptoms (such as suicidal ideation); (2) comorbid Axis I disorders; (3) serious medical or neurological conditions; (such as brain tumors, epilepsy, degenerative disorders, liver failure, cancers, etc.,); (4) substance dependence (other than caffeine or nicotine); (5) intellectual disability (based on clinical judgment); (6) pregnancy/breastfeeding; (7) contraindication for the use of granisetron or sertraline; (8) history of the previous psychosurgery for OCD; (9) have a complete response with sertraline in their history. During the conduction of the trial, patients were not permitted to participate in any psychotherapeutic treatment. Furthermore, patients were excluded if they used any psychotropic drugs in the last 6 weeks [11, 12].

**Interventions**

Eligible participants were randomized to receive either granisetron, 1 mg twice per day, or placebo for 10 weeks. All participants, regardless of group assignment, also received sertraline, 100 mg/day for 4 weeks, and then gradually increased to 200 mg/day. To minimize the side effects to the lowest level, the dosage of sertraline increased slowly every week.

**Outcome**

Y-BOCS was used for the assessment of patients at baseline and at weeks 0, 4, 8, and 10 of therapy. Y-BOCS provides a rating scale for the severity of obsessive-compulsive symptoms [11, 12]. This clinician-rated scale contains 10 questions, each item rated from 0 (no symptoms) to 4 (extreme symptoms) [27]. The psychometric properties of the Persian version of Y-BOCS are approved in previous studies [28–30].

The primary outcome of the trial was the difference of total score of the Y-BOCS among the two groups and between the baseline and the end of the trial. The secondary outcome measure was Y-BOCS compulsion and obsession subscale score changes between two groups during the trial period, and also the complete response, partial response, and remission rates, defined as ≥35%, ≥25% decrease in, and ≤16 Y-BOCS total scores [31]. Moreover, adverse effects were monitored every four weeks using a systematic questionnaire and three open questions to include any other side effects not included in the questionnaire [32–34]. In case of observation of any serious adverse effects during the course of therapy, a physician assessed the potential role of the medication in inducing the adverse effects and omitted the patient from the trial.

Randomization, allocation, concealment, and blinding

Randomization of participants was conducted with a random permuted block method (ratio of 1:1 and blocks of four). The assigned group of each participant was printed consecutively and enveloped in similar in appearance. The allocation was not in reach of the participants or any outcome assessors. The statistical analyzer, randomizer, and outcome assessor each were separate individuals and were blinded to allocation. Also, granisetron and placebo tablets were similar in shape, color, size, and odor.

**Sample size and statistical analysis**

With a between-group difference of five points in Y-BOCS score, type I error of 5%, an effect size of 0.25, and power of 80%, using G-power 3.1.9.2 we calculated a sample size of 44 (22 in each group). Considering a drop-out rate of 30% [11, 12], our final sample size was calculated at 58 (29 in each group). IBM SPSS Statistic 23.0.0 (IBM Corporations, Somers, New York, USA) was used for the statistical analysis. Continuous variables were reported as mean ±SD and categorical variables as n (%). Mean differences (MDs) between groups were reported with their 95% confidence intervals. Fisher’s exact test, or χ²-test was used for the comparison among categorical variables. The independent samples t-test was conducted for the comparison of continuous variable values, respectively. The comparison of Y-BOCS total and subscale score changes in and between groups during the ten-week course of study was achieved by performing a two-factor, repeated-measure analysis of variance (ANOVA). Whenever sphericity of the data could not be assumed using the Mauchly’s test of sphericity, the Greenhouse-Geisser correction for degrees of freedom was used. Score changes from baseline in the participants of each group was examined using the paired sample t-test. A p-value level of ≤0.05 was defined as significant. Missing data was imputed with last observation carried forward (LOCF) method (a form of intention-to-treat method). The missing follow-up visits value was replaced by that participant’s previously observed value.

**Results**

**Participants**

One hundred and eight patients were screened primarily, while 58 patients were recruited (randomly assigned to groups of granisetron+sertraline or placebo+sertraline), and 45 patients completed the trial. The trial flow diagram and causes of dropouts are represented in Fig. 1. In the first 4 weeks there were 27 patients in the granisetron group and 21 patients in the placebo group. The Baseline characteristics are summarized for each group separately in Table 1.

**Y-BOCS total score**

The baseline Y-BOCS total score was not significantly different between the groups (MD (95%
CI) = 1.4 (−2.26, 5.10), p-value = 0.442) (Table 1). Total Y-BOCS score changes from baseline in the granisetron group at fourth and tenth week of the study was MD (95% CI) = 5.6 (1.21, 9.98) (p-value < 0.01) at week 4 and MD (95% CI) = 11.2 (6.65, 15.74) (p-value < 0.01) at the week 10, respectively. In the other hand, participants in the
placebo group experienced not significant Y-BOCS total score drop at the week 4 (MD (95% CI) = -2.9 (-6.47, 0.67) (p-value=0.1)), while Y-BOCS total score drop at week 10 /9MD (95% CI) = 8.4 (4.78,12.01) (p-value<0.01)). In the end, Repeated measures ANOVA revealed no significant difference for the time between granisetron and placebo groups (Greenhouse-Geisser F(2.240,96.307) = 2.31, p-value<0.09). (Fig. 2) (Table 2).

At the end of the study, no significant difference was observed between the granisetron and the placebo group neither in partial response (20 patients -80%− vs. 14 −70%−, p-value=0.43) nor in remission rate (15 -60%− vs. 7 −35%−, p-value=0.09). Nonetheless, a significant difference was observed in the complete response rate (20 −80%− vs. 8 −40%−, p-value=0.01).

**Y-BOCS obsession subscale score**

The baseline Y-BOCS obsession subscale score did not significantly differ among treatment groups (MD (95% CI) = 1.87 (-0.11,3.85), p-value=0.06) (Table 1). Obsession Y-BOCS score changes from baseline in the granisetron group at the week 4 and the week 10 of the study was MD (95% CI) = 3.92 (1.86,5.97) (p-value<0.01) at the week 4 and MD (95% CI) = 7.62 (5.40,9.83) (p-value<0.01)
at the week 10, respectively. Participants in the placebo group experienced not significant Y-BOCS total score drop at the week 4 (MD (95% CI)=1.75 (-0.71,4.21) (p-value 0.15)) but their score change mean differences were MD (95% CI)=4.7 (2.39,7.00) (p-value <0.01) at the week 10. The time×treatment group interaction analysis by repeated-measures ANOVA revealed that granisetron group participants significantly experienced higher Y-BOCS obsession subscale score decrease (Greenhouse-Geisser F(2.32,97.57)=4.52,p-value=0.01) (Table 2). The Y-BOCS obsession subscale score change trend for each group is presented in Fig. 3.

Y-BOCS compulsion subscale score
The baseline Y-BOCS compulsion subscale score did not significantly differ among treatment groups (MD (95% CI) =-0.02 (-2.7,2.66), p-value=0.98)) (Table 1). Compulsion Y-BOCS score changes from baseline in the granisetron group at the week 4 was not significant but they experienced a significant drop at the week 10 of the study was MD (95% CI)=3.64 (0.73,6.54) (p-value 0.01).
Similarly, in the placebo group the change from the baseline was not significant in the week 4 but they experienced significant Y-BOCS compulsion score drop at the week 10 (MD (95% CI)=3.45 (1.22,5.67) (p-value<0.01)). The time×treatment group interaction analysis by repeated-measures ANOVA revealed no significant difference (Greenhouse-Geisser F(2,13,91.97)=0.315,p-value=0.74) (Table 2). The Y-BOCS compulsion subscale score change trend for each group is presented in Fig. 4.

### Adverse effects

Adverse events were recorded during the study. Side effects were mild and did not result in withdrawal. The frequency of side effects was not different between the two groups (Table 3).

### Discussion

The results showed a greater reduction in Y-BOCS total score, as well as its subscales in patients treated by granisetron plus sertraline in comparison with placebo plus sertraline. However, this difference was statistically significant only for the obsession subscale. Furthermore, our trial showed more partial responses, complete responses, and remission rates among patients receiving granisetron in comparison with placebo. Despite the difference in remission rates between the two groups (60% in the granisetron arm, and 35% in the placebo arm), the only difference in the complete response rate was statistically significant. This result may be explained by the small sample size of our study. Interestingly, our study showed that the rate of observed side effects was not significantly different between the granisetron and placebo groups.

The inclusion of OCD patients scoring at least 21 at the Y-BOCS (moderate to severe OCD), may have caused the statistical insignificance between the two groups. The high score in the baseline caused a large reduction in the absolute scores in both arms and this simultaneous large reduction could alter the significance of change difference between two groups.

The findings of our study are in agreement with previous trials and our hypothesis, which stated granisetron is an effective and well-tolerated agent to be used as adjuvant therapy to SSRIs for the treatment of OCD. To the best of our knowledge, the current study is the first 10-week double-blind randomized placebo-controlled trial to investigate the efficacy and safety of granisetron as adjuvant therapy to sertraline for moderate to severe OCD. In a recent study, Askari et al. reported that granisetron augmentation of fluvoxamine results in a greater reduction in OCD symptoms compared to a placebo[15]. They also reported significantly higher remission and complete response rates among patients in the granisetron group[15]. Our findings are in agreement with their report. Similar to our results, Askari et al. reported the safety and well-tolerability of granisetron plus fluvoxamine in comparison with placebo plus fluvoxamine[15]. However, we believe that our trial has some strengths in comparison with their trial. The key strengths of the present study are its larger sample size and longer duration of follow-up. Moreover, we used sertraline as a standard treatment of OCD for both granisetron and placebo groups. It is well-known that sertraline has the lowest drug-drug interaction among SSRIs approved for the treatment of OCD[24], and it seems to be the best option for adjuvant therapy. In the same vein, Sharafkhani et al. (2019) reported the efficacy of granisetron in patients with treatment-resistant OCD in a 14-week trial in comparison with the ondansetron arm and placebo arm. Although they reported the efficacy of granisetron in the treatment of the patients, they concluded that ondansetron is a superior option to granisetron[19]. The results of their study are hardly comparable to ours because the

### Table 2: Comparison of Yale-Brown obsessive-compulsive scale (Y-BOCS) subscales score change from baseline for treatment groups

| Y-BOCS subscale score reduction | Treatment group | Mean ± SD | MD (95% CI) | p-Value | Mean ± SD | MD (95% CI) | p-Value |
|--------------------------------|----------------|----------|-------------|---------|----------|-------------|---------|
|                                | granisetron + sertraline |           |             |         | placebo + sertraline |           |         |
| Obsession                      | Week 4          | 12.7 ± 4.36 | 3.92 (1.86–5.97) | 0.0003 | 13.4 ± 4.11 | 1.75 (–0.71–4.21) | 0.15    |
|                               | Week 8          | 10.41 ± 4.4 | 6.21 (4.14–8.27) | 0.0001 | 11.45 ± 3.66 | 3.3 (0.97–5.62) | 0.006   |
|                               | Week 10         | 9 ± 4.87   | 7.62 (5.40–9.83) | 0.0001 | 10.05 ± 3.6 | 4.7 (2.39–7.00) | 0.0002  |
| Compulsion                     | Week 4          | 10.8 ± 5.15 | 1.68 (–1.20–4.56) | 0.24  | 11.55 ± 3.8 | 0.95 (–1.24–3.14) | 0.38    |
|                               | Week 8          | 4.93 ± 4.86 | 3.16 (0.35–5.96) | 0.02  | 9.45 ± 3.84 | 3.05 (0.84–5.25) | 0.007   |
|                               | Week 10         | 8.84 ± 5.21 | 3.64 (0.73–6.54) | 0.01  | 9.05 ± 3.91 | 3.45 (1.22–5.67) | 0.003   |
| Total                          | Week 4          | 23.32 ± 8.83 | 5.6 (1.21–9.98) | 0.013 | 24.6 ± 6.42 | 2.9 (–6.47–0.67) | 0.10    |
|                               | Week 8          | 19.6 ± 8.55 | 9.32 (5.01–13.62) | 0.0001 | 20.9 ± 6.19 | 6.6 (3.09–10.10) | 0.0005  |
|                               | Week 10         | 17.72 ± 9.34 | 11.2 (6.65–15.74) | 0.0001 | 19.1 ± 6.51 | 8.4 (4.78–12.01) | 0.001   |

SD: standard deviation; Y-BOCS: Yale-Brown Obsessive–Compulsive Scale; CI: confidence interval; MD: mean difference.
The present study was performed on patients with moderate to severe OCD, not treatment-resistant patients.

Although the evidence presented thus far supports the efficacy and safety of 5HT₃ receptor antagonists such as ondansetron and tropisetron in the treatment of OCD patients [12, 16, 17], a recent systematic review concluded that more clinical trials are needed to confirm the efficacy of these agents as treatment options for OCD[18].

The exact mechanism of 5HT₃ receptor antagonists in the treatment of OCD symptoms is not yet well-known. Some researchers have reported that the 5HT₃ antagonists may ameliorate dopamine hyperactivity in ventral tegmental area in animal models[35], which is one of the known dysregulated systems in OCD, more specifically, due to its importance in reward circuity[36]. Another possible mechanism is the amelioration of dopaminergic activity in prefrontal areas, particularly rich in 5HT₃ receptors [37, 38]. The efficacy of dopamine antagonists in the treatment of OCD, which has been shown in previous studies, supports this hypothesis as well[39, 40].

On the other hand, 5HT₃ antagonists modulate the glutamatergic system through N-methyl d- aspartate (NMDA) receptor antagonism. Recently, augmentation

---

**Table 3** Frequency of adverse events in the two groups

| Adverse events   | Treatment group                     |  |  |  |
|------------------|-------------------------------------|---|---|---|
|                  | granisetron + sertraline            | N | % | N | % | p-value |
| Muscle pain      | 1                                   | 3.7 | 0 | 0 | 0 | 0.99 |
| Headache         | 1                                   | 3.7 | 0 | 0 | 0 | 0.99 |
| Diarrhea         | 0                                   | 0 | 0 | 1 | 4.8 | 0.43 |
| Constipation     | 1                                   | 3.7 | 0 | 0 | 0 | 0.99 |
| Decreased libido | 3                                   | 11.1 | 1 | 4.8 | 0.62 |
| Decreased appetite | 1                                  | 3.7 | 0 | 0 | 0 | 0.99 |
| Lightheadness    | 1                                   | 3.7 | 1 | 4.8 | 0.99 |
| Tremor           | 1                                   | 0 | 0 | 0 | 0 | 0.99 |
| Skin lesions     | 1                                   | 0 | 0 | 0 | 0 | 0.99 |
| Motor tic        | 0                                   | 0 | 1 | 4.8 | 0.43 |
| Palpitation      | 1                                   | 3.7 | 0 | 0 | 0 | 0.99 |
| Insomnia         | 2                                   | 7.4 | 1 | 4.8 | 0.99 |
| Itching          | 0                                   | 0 | 1 | 4.8 | 0.43 |
| Restlessness     | 0                                   | 0 | 1 | 4.8 | 0.43 |
| Vomiting         | 1                                   | 3.7 | 0 | 0 | 0 | 0.99 |

N: number; %: percentage among treatment group

---

**Fig. 4** Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) compulsion subscale score trend for each group during the trial course
strategies using glutamatergic agents has been explored, with promising results, in patients with OCD [11, 28, 41].

**Limitations**

Finally, some important limitations need to be considered. First, a 10-week trial for following up OCD patients is a little short and a longer study is suggested. As we thought that the inclusion of moderate to severe OCD patients may have driven the absolute score reduction in both arms and caused an insignificant difference between the two groups, performing other similar studies on patients with lower Y-BOCS scores can be valuable. Also, the rate of score changes that we used to define partial and complete response and remission are higher in some other studies. Using those definitions can affect our results. Additionally, our study was not performed on treatment-resistant OCD patients and the findings cannot be generalized to this population.

**Conclusion**

Taken together, these results suggest that granisetron augmentation of sertraline may increase the rate of response in patients with moderate to severe non-refractory OCD. Further studies are suggested in this regard. There is abundant room for further progress in determining the exact mechanism of action of granisetron in the treatment of OCD.

**List of abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| OCD | Obsessive-Compulsive Disorder |
| NMDA | N-Methyl-D-aspartate |
| SSRI | selective serotonin reuptake inhibitor |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders V |
| Y-BOCS | Yale-Brown obsessive compulsive scale |
| ERP | exposure and response prevention |
| 5-HT3 | 5-hydroxytryptamine receptor type 3 |
| ANOVA | analysis of variance |
| CI | confidence interval |
| SD | standard deviation |

**Acknowledgements**

This study was Dr. A. Ghobadian's postgraduate thesis toward the Iranian Board of Psychiatry.

**Authors' contributions**

AG, BS, LK, MEA and MS made substantial contributions to the conception and design of the work. AG, BS, MY and MS have substantial contribution in data gathering. SM and MS analyzed and interpreted the data. AG, SM, LK and MS have major contribution in writing the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Iran University of Medical Sciences (Grant no: 97-4-23-13222).

**Data availability**

The datasets generated and/or analysed during the current study are not publicly available due to confidentiality concerns (in the informed consent, we have made a commitment to the participants to publish only the general and group results of the study) but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The trial was approved by the ethics committee of Iran University of Medical Sciences institutional review board (IRB: IR.IUMS.REC.1398.060, grant number: 97-4-23-13222) and conducted according to the Declaration of Helsinki and subsequent revisions. Informed consent was obtained from all subjects and their legal guardian(s). Patients were informed that the nature of their participation was a voluntary activity and that they had the right to leave the trial at any time with no negative effect regarding their treatment. The trial was registered at the Iranian Registry of Clinical Trials (www.irct.ir, IRCT ID: IRCT20170123032145N3).

**Consent for publication**

Not applicable.

**Competing interests**

The authors have no conflicts of interest to report.

**Author details**

1. Mental Health Research Center, Psychosocial Health Research Institute (PHRI), Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2. Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
3. Mental Health Research Center (MHRC), School of Behavioral Sciences and Mental Health, Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, Iran
4. Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
5. Brain and Cognition Clinic, Institute for Cognitive Sciences Studies, Tehran, Iran

**Received:** 2 December 2021 / **Accepted:** 2 September 2022

**Published online:** 27 September 2022

**References**

1. Kanno M, Golding JM, Soensson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45(2):1094–9.
2. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: A world view. The Journal of clinical psychiatry. 1997.
3. Hirschl M, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317(13):1358–67.
4. Thomsen PH. Obsessive–compulsive disorders. Eur Child Adolesc Psychiatry. 2013;22(1):23–8.
5. Albert U, Maina G, Bogetto F, Charle A, Mataix-Cols D. Clinical predictors of health-related quality of life in obsessive-compulsive disorder. Compr Psychi atr. 2010;51(2):193–200.
6. DuPont RL, Rice D, Shiaki S, Rowland C. Economic costs of obsessive-compulsive disorder. Med interface. 1995;8(4):102–9.
7. Sebell PJ, Hollander E. Management of obsessive-compulsive disorder. F1000prime reports. 2014.6.
8. Foa EB, Liebowitz MR, Kazak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder: Am J Psychiatry. 2005;162(1):151–61.
9. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. The Journal of clinical psychiatry. 1999.
10. Erzegovesi S, Cavallini MC, Cavedini P, Dafena G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001;21(5):488–92.
11. Arabadeh S, Shalhousine M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(12):1267–73.
compulsive disorder: A randomized double-blind, placebo-controlled study. Hum Psychopharmacol Clin Exp. 2017;32(4):3584.

12. Shalbafan M, Malekpour F, Tadayon Najafabadi B, Gharemani K, Dastgheib S-A, Mosalavat A, et al. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019;33(11):1407–14.

13. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004;9(6):673–86.

14. Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130(3):338–47.

15. Askari N, Moin M, Sanati M, Tadjini M, Modabbernia A, Najand B, et al. Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder. CNS Drugs. 2012;26(10):883–92.

16. Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2014;29(6):344–50.

17. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonergic reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014;24(3):375–80.

18. Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Calvioni G, et al. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review. Hum Psychopharmacology: Clin Experimental. 2015;30(2):70–84.

19. Shara-Rahim M, Aghakarim Alamdar M, Massoudifar A, Abdolrzaaghnejad A, Ebrami-Momfared M, Saber R, et al. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol. 2019 Sep;34(9):222–3. PubMed PMID: 31058716. Epub 2019/05/07. eng.

20. Bhikram T, Abu-Joudé E, Sandor P. OCD: obsessive-compulsive… disgust? The role of disgust in obsessive–compulsive disorder. J Psychiatry Neurosci. 2017;42(5):300.

21. Andrews PL, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108–21.

22. Tuerker KJ, Limebeer CL, Fletcher PJ, Parker LA. Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT3 receptor in the posterior and anterior insular cortex. J Neurosci. 2012;32(40):13709–17.

23. Fonarow M, Martino A. Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive disorder patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report. Ann Gen Psychiatry. 2010;9(1):9.

24. Mohseni-Bandpey R, Moradi Chemeh F, Shalbafan M, Myoclonus as a Single Side Effect of Combination of Selective Serotonin Reuptake Inhibitors (SSRIs) and Clomipramine: Three Case Reports. J Mazandaran Univ Med Sci. 2010;21(1):59–62.

25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. 2013.

26. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown obsessive compulsive scale: II. Validity Archives of general psychiatry. 1989;46(11):1012–16.

27. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fischmann RL, Hill CL, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–11.

28. Esalatmanesh S, Abirhami Z, Zeinoddini A, Rahimnejad F, Sadeghi M, Najjarzadegan MR, et al. Mirtazapine combination therapy with fluvoxamine in moderate-to severe obsessive–compulsive disorder: A placebo-controlled, double-blind, randomized trial. J Neuropsychiatry Clin Neurosci. 2016;28(1):517–26.

29. Yousezadeh F, Sahelbolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, et al. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. International Clinical Psychopharmacology. 2020.

30. Shalbafan M, Mohammadnejad P, Shariat S-V, Alavi K, Zeinoddini A, Salehi M, et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48(4–5):136–40.

31. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400–12.

32. Ghajar A, Khoie-Ardakani M-R, Shahmohadi Z, Alavi A-R, Afarideh M, Shalbafan M-R, et al. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Res. 2018;262:94–101.

33. Araminia B, Shalbafan M, Mortezaei A, Shirazi E, Ghaffari S, Sahelbolzamani E, et al. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord. 2020;267:131–6.

34. Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, et al. Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. Advances in Integrative Medicine. 2019.

35. Roddi ZA, Gryszewska VE, Toalston JE, Oster SM, J-D, Bell RL, et al. The reinforcing actions of a serotonin-5 receptor agonist within the ventral tegmental area: evidence for subregional and genetic differences and involvement of dopamine neurons. J Pharmacol Exp Ther. 2007;321(3):1003–12.

36. Figue M, Vink M, de Geus F, Vulinik N, Veitman DJ, Westenberg H, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry. 2011;69(9):867–74.

37. Meneses A. 5-HT system and cognition. Neurosci Biobehavioral Reviews. 1999;23(8):1111–25.

38. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1996;51(3):215–35.

39. Bloch M, Landerer-Weisenberger A, Kelmendi B, Coric V, Bracken M, Leckman J. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622–32.

40. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. J Neuropsychopharmacol. 2013;36(3):557–74.

41. Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis. BMC Pharmacology and Toxicology. 2021;2021/11/04:22(1):69.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.